Jai Sidpra,Sniya Sudhakar,Asthik Biswas,Flavia Massey,Valentina Turchetti,Tracy Lau,Edward Cook,Javeria Raza Alvi,Hasnaa M Elbendary,Jerry L Jewell,Antonella Riva,Alessandro Orsini,Aglaia Vignoli,Zara Federico,Jessica Rosenblum,An-Sofie Schoonjans,Matthias de Wachter,Ignacio Delgado Alvarez,Ana Felipe-Rucián,Nourelhoda A Haridy,Shahzad Haider,Mashaya Zaman,Selina Banu,Najwa Anwaar,Fatima Rahman,Shazia Maqbool,Rashmi Yadav,Vincenzo Salpietro,Reza Maroofian,Rajan Patel,Rupa Radhakrishnan,Sanjay P Prabhu,Klaske Lichtenbelt,Helen Stewart,Yoshiko Murakami,Ulrike Löbel,Felice D'Arco,Emma Wakeling,Wendy Jones,Eleanor Hay,Sanjay Bhate,Thomas S Jacques,David M Mirsky,Matthew T Whitehead,Maha S Zaki,Tipu Sultan,Pasquale Striano,Anna C Jansen,Maarten Lequin,Linda S de Vries,Mariasavina Severino,Andrew C Edmondson,Lara Menzies,Philippe M Campeau,Henry Houlden,Amy McTague,Stephanie Efthymiou,Kshitij Mankad

Abstract:Inherited glycosylphosphatidylinositol deficiency disorders (IGDs) are a group of rare multisystem disorders arising from pathogenic variants in glycosylphosphatidylinositol anchor pathway (GPI-AP) genes. Despite associating 24 of at least 31 GPI-AP genes with human neurogenetic disease, prior reports are limited to single genes without consideration of the GPI-AP as a whole and with limited natural history data. In this multinational retrospective observational study, we systematically analyse the molecular spectrum, phenotypic characteristics, and natural history of 83 individuals from 75 unique families with IGDs, including 70 newly reported individuals: the largest single cohort to date. Core clinical features were developmental delay or intellectual disability (DD/ID, 90%), seizures (83%), hypotonia (72%), and motor symptoms (64%). Prognostic and biologically significant neuroimaging features included cerebral atrophy (75%), cerebellar atrophy (60%), callosal anomalies (57%), and symmetric restricted diffusion of the central tegmental tracts (60%). Sixty-one individuals had multisystem involvement including gastrointestinal (66%), cardiac (19%), and renal (14%) anomalies. Though dysmorphic features were appreciated in 82%, no single dysmorphic feature had a prevalence >30%, indicating substantial phenotypic heterogeneity. Follow-up data were available for all individuals, 15 of whom were deceased at the time of writing. Median age at seizure onset was 6 months. Individuals with variants in synthesis stage genes of the GPI-AP exhibited a significantly shorter time to seizure onset than individuals with variants in transamidase and remodelling stage genes of the GPI-AP (P=0.046). Forty individuals had intractable epilepsy. The majority of individuals experienced delayed or absent speech (95%); motor delay with non-ambulance (64%); and severe-to-profound DD/ID (59%). Individuals with a developmental epileptic encephalopathy (51%) were at greater risk of intractable epilepsy (P=0.003), non-ambulance (P=0.035), ongoing enteral feeds (P<0.001), and cortical visual impairment (P=0.007). Serial neuroimaging showed progressive cerebral volume loss in 87.5% and progressive cerebellar atrophy in 70.8%, indicating a neurodegenerative process. Genetic analyses identified 93 unique variants (106 total), including 22 novel variants. Exploratory analyses of genotype-phenotype correlations using unsupervised hierarchical clustering identified novel genotypic predictors of clinical phenotype and long-term outcome with meaningful implications for management. In summary, we expand both the mild and severe phenotypic extremities of the IGDs; provide insights into their neurological basis; and, vitally, enable meaningful genetic counselling for affected individuals and their families.

Significantly different clinical phenotypes associated with mutations in synthesis and transamidase+remodeling glycosylphosphatidylinositol (GPI)-anchor biosynthesis genes

The clinical and genetic spectrum of inherited glycosylphosphatidylinositol deficiency disorders

Characterization of glycosylphosphatidylinositol biosynthesis defects by clinical features, flow cytometry, and automated image analysis

Phenotype-genotype correlations of PIGO deficiency with variable phenotypes from infantile lethality to mild learning difficulties

Inherited glycosylphosphatidylinositol deficiency: a review from molecular and clinical perspectives

Missense variant in PIGM associated with severe cystic encephalomalacia and portal vein thrombosis: Phenotypic and genotypic expansion of the glycosylphosphatidylinositol biosynthesis defect-1 (GPIBD1)

PIGO-CDG: A case study with a new genotype, expansion of the phenotype, literature review, and nosological considerations

Genetic Analysis of Two Novel GPI Variants Disrupting H Bonds and Localization Characteristics of 55 Gene Variants Associated with Glucose-6-phosphate Isomerase Deficiency

Congenital diaphragmatic hernia in siblings with PIGA-related congenital disorder of glycosylation

Clinical and Molecular Spectrum of Glucose-6-Phosphate Isomerase Deficiency. Report of 12 New Cases

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Defining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases

Evolutionary rate covariation is pervasive between glycosylation pathways and points to potential disease modifiers

The novel compound heterozygous variants identified in a Chinese family with glucose phosphate isomerase deficiency and pathogenicity analysis

Cerebral visual impairment and intellectual disability caused by PGAP1 variants

A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

Rare Genetic Developmental Disabilities: Mabry Syndrome (MIM 239300) Index Cases and Glycophosphatidylinositol (GPI) Disorders

Drosophila models of phosphatidylinositol glycan biosynthesis class A congenital disorder of glycosylation (PIGA-CDG) mirror patient phenotypes

Sugary Logistics Gone Wrong: Membrane Trafficking and Congenital Disorders of Glycosylation

GPIアンカーとその欠損症

Macrocephaly and Digital Anomalies Expand the Phenotypic Spectrum of PGAP2 Variants in Hyperphosphatasia with Impaired Intellectual Development Syndrome 3 (HPMRS3)